Proteomics

Dataset Information

0

The immunopeptidome and proteome of DIPG

ABSTRACT: DIPG is a devastating paediatric and young adult brainstem tumour with no cure and a median overall survival of 9 months. Cellular immunotherapy approaches require specific targeting of unique and tumour specific cell surface antigens, however, there is a paucity of known targets for DIPG. Here we used a proteomics platform approach to interrogate an array of patient derived DIPG cell lines to facilitate a multi-omics based approach to identify cell surface protein candidates enriched or unique to DIPG.

INSTRUMENT(S): Orbitrap Fusion, Q Exactive

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Brain

SUBMITTER: Kirti Pandey  

LAB HEAD: Anthony Wayne Purcell

PROVIDER: PXD038271 | Pride | 2023-09-25

REPOSITORIES: Pride

Json Xml

Dataset's files

Source:
Action DRS
20200226_SRKP_DIPG_bb72_SU27.mgf Mgf
20200226_SRKP_DIPG_bb72_SU27.raw Raw
20200226_SRKP_DIPG_bb72_SU27_peptides_1_1_0.mzid.gz Mzid
20200226_SRKP_DIPG_bb72_SU35.mgf Mgf
20200226_SRKP_DIPG_bb72_SU35.raw Raw
Items per page:
1 - 5 of 87
altmetric image

Publications

A combined immunopeptidomics, proteomics, and cell surface proteomics approach to identify immunotherapy targets for diffuse intrinsic pontine glioma.

Pandey Kirti K   Wang Stacie S SS   Mifsud Nicole A NA   Faridi Pouya P   Davenport Alexander J AJ   Webb Andrew I AI   Sandow Jarrod J JJ   Ayala Rochelle R   Monje Michelle M   Cross Ryan S RS   Ramarathinam Sri H SH   Jenkins Misty R MR   Purcell Anthony W AW  

Frontiers in oncology 20230811

<h4>Introduction</h4>Diffuse intrinsic pontine glioma (DIPG), recently reclassified as a subtype of diffuse midline glioma, is a highly aggressive brainstem tumor affecting children and young adults, with no cure and a median survival of only 9 months. Conventional treatments are ineffective, highlighting the need for alternative therapeutic strategies such as cellular immunotherapy. However, identifying unique and tumor-specific cell surface antigens to target with chimeric antigen receptor (CA  ...[more]

Similar Datasets

Proteomics H3.3K27M HLA-A2 is not an effective immunotherapy target for diffuse midline glioma
2023-10-24 | PXD038371 | Pride
Proteomics The HLA peptide repertoire of SaOS-2 cell line transfected with TP53 protein
2022-10-13 | PXD034044 | Pride
Proteomics Immunopeptidome of an acute myeloid leukemia cell line THP1
2020-05-13 | PXD015039 | Pride
Proteomics Proteome of SUDIPG, SF7761 and primary non diseased brain samples
2023-10-24 | PXD038372 | Pride
Proteomics MHC peptides presentation is limited by availability of empty HLA molecules rather than the supply of peptides ligands
2018-05-10 | PXD007596 | Pride
Proteomics DDA acquisition of the immunopeptidomes of C1R-B*57:01 and C1R-A*02:01 cell lines
2023-02-13 | PXD034429 | Pride
Proteomics Presentation of DNAJB1-PRKACA fusion neoantigens by different HLA class I alleles
2024-05-24 | PXD042316 | Pride
Proteomics Hotspot DNMT3A and IDH1/2 Mutations in Acute Myeloid Leukemia and Their Relevance as Targets for Immunotherapy
2024-06-23 | PXD050560 | Pride
Proteomics Tumour-associated antigenic peptides are present in the HLA class I ligandome of cancer cell line derived extracellular vesicles.
2022-04-01 | PXD025345 | Pride
Proteomics Thermostability profiling of MHC-bound peptides: a new dimension in immunopeptidomics and design of immunotherapeutics.
2020-11-30 | PXD017824 | Pride